EDVA 8-K/A
Endovia Health Sciences, Inc. (EDVA)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
(State or other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
||
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area
code:
(Former name or former address, if changed since last report.): n/a
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of each exchange on which registered | ||
EXPLANATORY NOTE
This Current Report on Form 8-K/A is being filed solely to amend the Current Report on Form 8-K which was filed with the Securities and Exchange Commission on July 29, 2026 to correct the hyperlink to Exhibit 10.1 which errantly included the wrong document due to an administrative which occurred in the EDGAR filing process. The correct hyperlink for Exhibit 10.1 is included in this Form 8-K/A.
Item 1.01 Entry into a Material Definitive Agreement
On July 28, 2026, Splash Beverage Group, Inc. (the “Company”) and Argent BioPharma Limited (ASX/LSE: RGT) (the “Licensor”) entered into an addendum (the “Addendum”) to that certain exclusive global license agreement for CannEpil®, dated July 6, 2026 (the “License Agreement”). Pursuant to the Addendum, the License Agreement was amended to: (i) expand the field of use under the License Agreement to include veterinary applications; (ii) provide for an amended royalty rate payable to the Licensor equal to 10% of Net Revenue (as defined in the License Agreement) attributable to veterinary applications and 15% of Net Revenue attributable to human applications; and (iii) extend various deadlines provided for under the License Agreement. The Company previously disclosed the License Agreement and filed a copy thereof as Exhibit 10.1 in the Company’s Current Report on Form 8-K filed on July 6, 2026.
The foregoing description of the Addendum does not purport to be complete and is qualified in its entirety by reference to the full text of the Addendum, a copy of which is filed as Exhibit 10.1 and is incorporated herein by reference.
Item 7.01 Regulation FD Disclosure
On July 29, 2026, Splash Beverage Group, Inc. issued a press release announcing that it has expanded its exclusive global license for CannEpil® with Argent BioPharma Limited (ASX/LSE: RGT) to include veterinary applications. A copy of the press release is furnished as Exhibit 99.1 of this Current Report on Form 8-K.
The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| Exhibit | Description | |
| 10.1 | Addendum No. 1 to the Exclusive License Agreement, dated July 29, 2026, by and between the Company and Argent BioPharma Limited | |
| 99.1 | Press Release dated July 29, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SPLASH BEVERAGE GROUP, INC. | ||
| Date: July 30, 2026 | By: | /s/ Brady Cobb |
| Name: | Brady Cobb | |
| Title: | Interim Chief Executive Officer | |
EXHIBIT 10.1
ADDENDUM NO. 1
TO THE EXCLUSIVE LICENSE AGREEMENT
This Addendum No. 1 (this “Addendum”) is entered into as of July 28, 2026 (the “Addendum Effective Date”), by and between Argent Biopharma Limited (“RGT”) and Splash Beverage Group, Inc. (“SBEV”), and amends that certain Exclusive License Agreement dated July 6, 2026 (the “Agreement”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement.
RECITALS
WHEREAS, the Parties desire to expand the Field under the Agreement to include both human and veterinary purposes;
WHEREAS, SBEV intends to enter into a Development and Collaboration Agreement with Lupvindol UK Limited (the “Collaboration Agreement”) for the purpose of advancing the Licensed Product as an Investigational Veterinary Product through the FDA Center for Veterinary Medicine INAD and Conditional Approval pathway;
WHEREAS, in consideration of the expanded Field and the Collaboration Agreement, the Parties desire to establish differentiated royalty rates for the Human Field and the Veterinary Field (as defined below);
WHEREAS, the Parties desire to revise certain delivery and execution deadlines under the Agreement; and
WHEREAS, the Parties desire to amend the Agreement to reflect such changes.
NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, the Parties agree as follows:
1. Amendment to Definition of “Field” (Section 1.9). Section 1.9 of the Agreement is hereby deleted in its entirety and replaced with the following:
“1.9. ‘Field’ means: (a) the treatment, prevention, management, or amelioration of drug-resistant epilepsy, refractory epilepsy, seizure disorders, and all related neurological conditions in humans, including as an adjunctive or add-on therapy (the ‘Human Field’); and (b) veterinary purposes, including the treatment, prevention, management, or amelioration of diseases, conditions, or disorders in non-human animals, including as an adjunctive or add-on therapy (the ‘Veterinary Field’).”
2. Amendment to Running Royalty (Section 4.2). Section 4.2 of the Agreement is hereby deleted in its entirety and replaced with the following:
“4.2. Running Royalty. SBEV shall pay to RGT a royalty (the ‘Royalty’) calculated as follows: (a) fifteen percent (15%) of Net Revenue attributable to the Human Field; and (b) ten percent (10%) of Net Revenue attributable to the Veterinary Field. The Royalty shall be payable for so long as SBEV or any Affiliate or sublicensee sells the Licensed Product in the Territory and the longer of: (i) ten (10) years following the First Commercial Sale in each country; or (ii) the expiration of the last-to-expire Patent claiming the Licensed Product in each country. For sales by sublicensees, the Royalty shall be calculated on the Net Revenue received by SBEV from such sublicensee.”
3. Amendment to Product Specifications (Schedule A). The reference in Schedule A to delivery of Product Specifications “within 30 days of the Effective Date” is hereby deleted and replaced with “within sixty (60) days after receipt by SBEV of the Data Package.”
4. Data Package (Section 5.6(a)). For the avoidance of doubt, the deadline for RGT to deliver the Data Package under Section 5.6(a) of the Agreement (sixty (60) days following the Effective Date) remains unchanged.
5. Amendment to Development Plan (Section 5.2). The first sentence of Section 5.2 of the Agreement is hereby amended by deleting “Within ninety (90) days following the Effective Date” and replacing it with “Within one hundred twenty (120) days after the date of receipt by SBEV of the Data Package”.
6. Amendment to Safety Data Exchange Agreement (Section 5.7(a)). The reference in Section 5.7(a) of the Agreement to execution of the Safety Data Exchange Agreement “within ninety (90) days after the Effective Date” is hereby deleted and replaced with “within one hundred twenty (120) days after the date of receipt by SBEV of the Data Package”.
7. Amendment to Supply Agreement and Quality Agreement (Section 5.9). The reference in Section 5.9(a) of the Agreement to execution of the supply agreement and quality agreement “within ninety (90) days following the Effective Date” is hereby deleted and replaced with “within one hundred twenty (120) days after the date of receipt by SBEV of the Data Package”.
8. Consent to Collaboration and Sublicense. RGT hereby acknowledges that SBEV intends to enter into the Collaboration Agreement with Lupvindol UK Limited (“Lupvindol”) for the purpose of advancing the Licensed Product as an Investigational Veterinary Product through the FDA Center for Veterinary Medicine INAD and Conditional Approval pathway. In furtherance thereof, and pursuant to Section 2.3 of the Agreement, RGT hereby consents to SBEV granting to Lupvindol a non-exclusive, non-transferable, non-sublicensable, royalty-free license during the term of the Collaboration Agreement to use, access, and reference the Intellectual Property solely within the Veterinary Field and the Territory, and solely to the extent necessary for Lupvindol to perform its obligations under the Collaboration Agreement. Such consent shall not relieve SBEV of any of its obligations under the Agreement, and SBEV shall remain primarily responsible for all obligations thereunder. RGT’s consent to the foregoing sublicense shall not be construed as consent to any other sublicense or grant of rights to any other third party.
9. Full Force and Effect. Except as expressly amended by this Addendum, the Agreement remains in full force and effect and is hereby ratified and confirmed.
10. Counterparts. This Addendum may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument.
11. Governing Law. This Addendum shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to its conflict of laws principles.
[Signature Page Follows]
IN WITNESS WHEREOF, the Parties have executed this Addendum as of the Addendum Effective Date.
| ARGENT BIOPHARMA LIMITED | ||
| By: | /s/ Roby Zomer | |
| Name: Roby Zomer | ||
| Title: Chairman | ||
| SPLASH BEVERAGE GROUP, INC. | ||
| By: | /s/ Brady Cobb | |
| Name: Brady Cobb | ||
| Title: Interim CEO | ||
EXHIBIT 99.1
Splash Beverage Group Expands CannEpil® Platform
into Veterinary Therapeutics, Establishing Second
FDA-Regulated Pharmaceutical Development Program
Expansion broadens CannEpil into veterinary therapeutics as Splash advances its cannabinoid pharmaceutical development platform
FORT LAUDERDALE, Fla., July 29, 2026— Splash Beverage Group, Inc. (NYSE American: SBEV) (“Splash” or the “Company”) today announced that it has expanded its exclusive global license for CannEpil® to include veterinary therapeutic applications, creating a second regulated pharmaceutical development platform alongside the Company’s existing human pharmaceutical program.
The expanded field of use grants Splash exclusive worldwide rights to develop, manufacture, commercialize, market and distribute CannEpil for veterinary diseases and conditions.
CannEpil is a proprietary pharmaceutical-grade cannabinoid formulation consisting of cannabidiol (CBD) and tetrahydrocannabinol (THC) isolates formulated in an oral liquid solution and manufactured under European Union Good Manufacturing Practice (EU-GMP) standards. Originally developed as a potential treatment for drug-resistant epilepsy, CannEpil has previously been supplied through physician-directed access programs in international markets and has been assigned an Investigational New Drug (IND) application number by the U.S. Food and Drug Administration for its human development program.
Splash intends to initially evaluate CannEpil for veterinary applications in companion-animal oncology and chronic pain management, with canine indications expected to represent the initial development focus. The Company intends to pursue U.S. regulatory approval through the FDA Center for Veterinary Medicine’s Investigational New Animal Drug (INAD) and Conditional Approval pathways.
Addressing Significant and Growing Companion-Animal Markets
The Company’s veterinary expansion positions CannEpil within two significant and growing areas of companion-animal medicine.
According to Grand View Research, the global veterinary pain management market was valued at approximately $2.6 billion in 2024 and is projected to reach approximately $3.8 billion by 2030, driven by increasing pet ownership, longer lifespans and growing demand for advanced veterinary care.
Companion-animal oncology represents another meaningful opportunity. Independent industry estimates place the global veterinary oncology market between approximately $900 million and $1.7 billion, depending on the products and services included, with continued long-term growth expected.
The underlying patient population is substantial. According to the Veterinary Cancer Society, one in four dogs will develop cancer during their lifetime, while approximately half of dogs over the age of ten will develop cancer. The U.S. National Cancer Institute estimates that approximately six million dogs are diagnosed with cancer each year in the United States.
“Expanding our exclusive CannEpil license into veterinary medicine materially broadens the value of the platform and provides access to significant companion-animal oncology and pain-management markets,” said Brady Cobb, Interim Chief Executive Officer of Splash Beverage Group. “Cancer and chronic pain affect millions of companion animals, yet treatment options remain limited in many indications. We believe CannEpil’s pharmaceutical-grade formulation warrants disciplined evaluation through the FDA veterinary process.”
Under the amendment, Splash will pay Argent BioPharma Limited a 10% royalty on net revenues generated from veterinary applications of CannEpil.
The Company is also finalizing a strategic joint venture with an established cannabinoid pharmaceutical company to lead CannEpil’s veterinary development program. The partner’s executive leadership includes experienced pharmaceutical development professionals with a demonstrated track record of advancing cannabinoid-based medicines through regulatory approval and commercialization. Splash expects to announce additional details regarding the collaboration in the near future.
Executing a Diversified Cannabinoid Health Sciences Strategy
“Our objective extends well beyond expanding the licensed field of use,” Cobb continued. “We are assembling a world-class development platform around CannEpil by partnering with experienced cannabinoid pharmaceutical executives who have successfully navigated complex regulatory pathways and helped bring cannabinoid medicines to market. We believe pairing differentiated intellectual property with proven scientific and regulatory expertise materially enhances our ability to create long-term shareholder value.”
“Splash is executing a disciplined strategy to build a diversified cannabinoid health sciences platform by commercializing existing international pharmaceutical assets, advancing FDA-regulated veterinary and human therapeutics, and developing innovative cannabinoid consumer wellness and beverage brands for global markets. The expansion of CannEpil into veterinary medicine represents another important milestone in executing that strategy and further positions Splash at the intersection of pharmaceutical innovation and cannabinoid science.”
The Company believes the expanded veterinary rights complement its broader strategy of commercializing pharmaceutical cannabinoid assets across multiple regulated healthcare markets. Actual development timelines, target indications, clinical requirements and regulatory pathways will be determined following engagement with the FDA and other applicable regulatory authorities.
There can be no assurance that CannEpil will receive Conditional Approval, full approval or any other regulatory authorization for veterinary use, or that any commercialization efforts will be successful.
About CannEpil®
CannEpil® is a proprietary pharmaceutical-grade cannabinoid formulation consisting of cannabidiol (CBD) and tetrahydrocannabinol (THC) isolates formulated in an oral liquid solution and manufactured under European Union Good Manufacturing Practice (EU-GMP) standards. Originally developed for drug-resistant epilepsy, CannEpil has previously been supplied through physician-directed access pathways in select international markets and is being advanced for additional pharmaceutical indications.
About Splash Beverage Group, Inc.
Splash Beverage Group, Inc. (NYSE American: SBEV) is a publicly traded company headquartered in Fort Lauderdale, Florida. The Company is pursuing a strategic transformation toward becoming a cannabinoid health, wellness, and biopharmaceutical platform through disciplined capital allocation, strategic investments, acquisitions, and other platform-building initiatives.
More Information
Splash Beverage Group
Contact Information
Splash Beverage Group
[email protected]
Media Contact
Angela Gorman
AMWPR
[email protected]
917-348-0083
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the Company’s plans to develop and commercialize CannEpil for veterinary applications; anticipated regulatory pathways, including the FDA Center for Veterinary Medicine’s Investigational New Animal Drug (INAD) and Conditional Approval processes; estimates and projections for the market for veterinary treatments including oncology and pain management uses, the completion of a proposed joint venture; the anticipated capabilities and experience of prospective development partners; the commercialization of international pharmaceutical assets; the development of additional cannabinoid therapeutics, wellness and beverage products; and the Company’s broader strategic initiatives including its strtagy of commercializing pharmaceutical cannabinoid assets across multiple regulated healthcare markets. Forward-looking statements are prefaced by words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “should,” “would,” “intend,” “potential,” “believe,” “estimate,” “forecast,” “project,” and similar words.
Forward-looking statements are based on current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results to differ materially. Actual results may differ materially from those contemplated by such forward-looking statements due to a variety of risks and uncertainties which include, among others, the possibility that the license and our efforts to develop and commercialize the licensed product do not yield the benefits anticipated or sought, the risk that we and the licensor are not able to obtain, maintain or protect intellectual property rights in the licensed product in jurisdictions in which we seek to develop and commercialize the product and that competitors market the same or similar products, our ability to negotiate ad execute a joint venture with a strategic collaborator to assist in our planned efforts in the veterinary treatment space, our need to comply with contractual obligations to maintain our rights and develop and commercialize the licensed product, our ability to raise the capital necessary to develop and commercialize the product and otherwise meet our working capital needs, our need to comply with extensive regulations including clinical testing before we can market the product in applicable jurisdictions including the U.S., our ability to recommence revenue generating activities with our limited staffing, and the status of evolving regulatory conditions within the cannabinoid and wellness industries, and our ability to regain and maintain compliance with American listing standards. There can be no assurance that CannEpil will receive regulatory approval for any indication or that any development or commercialization initiative will achieve its intended results.
Additional information concerning these and other risk factors is contained in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025 and the Final Prospectus on Form 424B3 filed on June 26, 2026. Any forward-looking statement made by the Company speaks only as of the date on which it is made.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Splash undertakes no obligation to update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable law.